Table 3

Participant outcomes

Baseline
mean (SD)
6 Months
mean (SD)
12 Months
mean (SD)
Secondary outcome evaluation
UPDRS Part III (OFF medication)*38.5 (11.4)N/AN/A
UPDRS Part III (OFF medication/OFF stimulation)*N/A30.5 (12.9)†30.9 (9.9)†
Modified Hoehn & Yahr (OFF-state)‡3.0 (0.7)2.5 (0.4)2.6 (0.7)
Combined therapy evaluation
UPDRS Part I§3.4 (2.2)3.1 (2.8)3.5 (2.1)
UPDRS Part II¶18.3 (6.7)13.3 (5.6)13.9 (5.8)
UPDRS Part III (ON medication)**18.3 (9.4)N/AN/A
UPDRS Part III (ON medication/ON stimulation)**N/A15.4 (6.4)14.3 (6.2)
Complications of therapy evaluation
UPDRS Part IV††6.8 (3.2)3.1 (2.0)3.1 (2.1)
 Dyskinesia items 32, 33, 341.9 (2.2)0.2 (0.6)0.1 (0.3)
Modified Hoehn & Yahr (ON-state)‡‡2.1 (0.5)2.1 (0.5)2.2 (0.4)
  • For all scales, higher scores indicate more severe parkinsonism.

  • *Motor examination while off therapy (range 0–108).

  • †P=0.002 main effect of time. Significant decrease at 6 months and 12 months versus baseline.

  • ‡Measured while off therapy (range 0–5).

  • §Mentation, behaviour and mood (range 0–16).

  • ¶Activities of daily living while on therapy (range 0–52).

  • **Motor examination while on therapy (range 0–108).

  • ††Complications of therapy (range 0–23).

  • ‡‡Measured while on therapy (range 0–5).

  • UPDRS, Unified Parkinson’s Disease Rating Scale.